谷歌浏览器插件
订阅小程序
在清言上使用

Personalized Dosimetry As a Key for Optimizing Radioligand Therapy (RLT) with 177Lu- or 177Lu/90y-Dota-tate in Patients with Well-Differentiated Neuroendocrine Tumors - an Update on the Initial Results of the DUONEN Multicenter Study

Endocrine Abstracts(2024)

引用 0|浏览15
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要